Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients with T2...

Descripción completa

Detalles Bibliográficos
Autores principales: Konya, Hiroyuki, Yano, Yuzo, Matsutani, Satoshi, Tsunoda, Taku, Ikawa, Takashi, Kusunoki, Yoshiki, Matsuo, Toshihiro, Miuchi, Masayuki, Katsuno, Tomoyuki, Hamaguchi, Tomoya, Miyagawa, Jun-ichiro, Namba, Mitsuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103926/
https://www.ncbi.nlm.nih.gov/pubmed/25050065
http://dx.doi.org/10.2147/TCRM.S46076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103926/
https://www.ncbi.nlm.nih.gov/pubmed/25050065
http://dx.doi.org/10.2147/TCRM.S46076

Ejemplares similares